论文部分内容阅读
选择３２例骨母细胞性肿瘤，包括１４例良性骨母细胞瘤、２例侵袭性骨母细胞瘤和１６例骨母细胞型骨肉瘤，用ＡＢＣ法作多种抗血清标记（ｖｉｍｅｎｔｉｎ、Ｓ－１００、α－ＡＴ、ｌｙｓｏｚｙｍｅ、Ｌｅｕ－７、Ｋ１２和ＣＥＡ）。结果显示：３２例肿瘤性骨母细胞ｖｉｍｅｎｔｉｎ均呈不同程度的阳性反应；在６例骨母细胞型骨肉瘤和１例侵袭性骨母细胞瘤中散在的单个细胞Ｓ－１００蛋白呈阳性反应，表明肿瘤性的骨母细胞具有软骨分化的潜能１２４例肿瘤中的多核巨细胞α－ＡＴ和１５例肿瘤中的多核巨细胞ｌｙｓｏｚｙｍｅ均呈不同程度的阳性反应，进一步证实这些细胞可能是组织细胞起源；６例骨母细胞型骨肉瘤和４例良性骨母细胞瘤中的骨样基质Ｌｅｕ－７呈阳性反应。
Thirty-two cases of osteoblastoma were selected, including 14 cases of benign osteoblastoma, 2 cases of invasive osteoblastoma, and 16 cases of osteoblast osteosarcoma. ABC method was used for multiple antiserum markers (vimentin, S- 100, α-AT, lysozyme, Leu-7, K12 and CEA). The results showed that 32 cases of tumorous osteoblasts showed vimentin positive reaction in different degrees; in 6 cases of osteoblast-type osteosarcoma and 1 case of invasive osteoblastoma, S100 protein scattered in single cells was positive. The potential of cartilage-differentiated osteoblasts to differentiate into cartilage was demonstrated in 124 tumors of multinucleated giant cells α-AT and in 15 tumors of multinucleated giant cell lysozyme. These positive reactions further confirmed that these cells may be histiocytic origin. The bone-like stroma Leu-7 was positive in 6 cases of osteoblastoma osteosarcoma and 4 cases of benign osteoblastoma.